Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Protein binding nkg2d, cd16 and tumor-associated antigen

A protein and antigen technology, applied in the direction of anti-animal/human immunoglobulin, hybrid immunoglobulin, animal/human protein, etc.

Pending Publication Date: 2020-06-12
DRAGONFLY THERAPEUTICS INC
View PDF17 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Other types of cancer also remain challenging to treat with existing treatment options

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Protein binding nkg2d, cd16 and tumor-associated antigen
  • Protein binding nkg2d, cd16 and tumor-associated antigen
  • Protein binding nkg2d, cd16 and tumor-associated antigen

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1-N

[0278] Example 1 - NKG2D binding domains bind to NKG2D

[0279] NKG2D binding domain binds to purified recombinant NKG2D

[0280] The nucleic acid sequence of human, mouse or cynomolgus NKG2D extracellular domains (ectodomains) is fused with the nucleic acid sequence encoding human IgG1 Fc domain, and introduced into mammalian cells for expression. After purification, the NKG2D-Fc fusion protein was adsorbed to the wells of a microplate. After blocking the wells with bovine serum albumin to prevent non-specific binding, the NKG2D binding domain was titrated and added to the wells pre-adsorbed with NKG2D-Fc fusion protein. Primary antibody binding was detected using a secondary antibody conjugated to horseradish peroxidase and specifically recognizing human kappa light chain to avoid Fc cross-reactivity. The substrate for horseradish peroxidase, 3,3',5,5'-tetramethylbenzidine (TMB), was added to the wells to visualize the binding signal, measured at 450 nM and corrected at ...

Embodiment 2

[0285] Example 2 - NKG2D Binding Domains Block Natural Ligand Binding to NKG2D

[0286] Competition with ULBP-6

[0287] The recombinant human NKG2D-Fc protein was adsorbed to the wells of a microplate, and the wells were blocked with bovine serum albumin to reduce non-specific binding. A saturating concentration of ULBP-6-His-biotin was added to the wells followed by NKG2D binding domain clones. After 2 hours of incubation, the wells were washed and ULBP-6-His-biotin still bound to NKG2D-Fc-coated wells was detected by streptavidin-coupled horseradish peroxidase and TMB substrate . Absorbance was measured at 450 nM and corrected at 540 nM. The specific binding of the NKG2D binding domain to the NKG2D-Fc protein was calculated from the percentage of ULBP-6-His-biotin blocked from binding to the NKG2D-Fc protein in the wells after background subtraction. Positive control antibodies (comprising heavy and light chain variable domains selected from SEQ ID NO: 101-104) and va...

Embodiment 3-N

[0294] Example 3 - NKG2D binding domain cloning activates NKG2D

[0295] The nucleic acid sequences of human and mouse NKG2D were fused to the nucleic acid sequence encoding the CD3ζ signaling domain to obtain chimeric antigen receptor (CAR) constructs. The NKG2D-CAR construct was then cloned into a retroviral vector using Gibson assembly and transfected into expi293 cells for retroviral production. EL4 cells were infected with NKG2D-CAR-containing virus together with 8 μg / mL polybrene. 24 hours after infection, the expression level of NKG2D-CAR in the EL4 cells was analyzed by flow cytometry, and clones expressing high levels of NKG2D-CAR on the cell surface were selected.

[0296] To determine whether NKG2D-binding domains activate NKG2D, they were adsorbed to wells of microplates and NKG2D-CAR EL4 cells were incubated on antibody fragment-coated wells in the presence of brefeldin-A and monensin Incubate for 4 hours. Intracellular TNF-[alpha] production, an indicator of N...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Multi-specific binding proteins that bind NKG2D receptor, CD16, and 5T4, a tumor-associated antigen selected from 5T4, GPNMB, FR-alpha, PAPP-A, and GPC3 are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.

Description

[0001] Cross References to Related Applications [0002] This application claims U.S. Provisional Patent Application No. 62 / 510,137, filed May 23, 2017, U.S. Provisional Patent Application No. 62 / 510,168, filed May 23, 2017, U.S. Provisional Patent Application No. 62 / 510,168, filed May 23, 2017 62 / 510,169, U.S. Provisional Patent Application Nos. 62 / 510,167, filed May 23, 2017, and 62 / 539,425, filed July 31, 2017, the contents of each of which are adopted in their entirety for all purposes Incorporated herein by reference. [0003] sequence listing [0004] This application contains a Sequence Listing, filed electronically in ASCII format and incorporated herein by reference in its entirety. The ASCII copy generated on May 21, 2018 is named DFY-018WO.txt and is 144kb in size. technical field [0005] The present invention relates to a multispecific binding protein that binds to NKG2D, CD16 and a tumor-associated antigen selected from 5T4, GPNMB, FR-α, PAPP-A and GPC3. Bac...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/395C07K16/28C07K16/30C07K16/46C07K19/00
CPCC07K14/7056C07K16/283C07K16/2851C07K2317/30C07K2317/31C07K2317/73C07K2317/94C07K2319/30A61P35/00C07K2317/732C07K2317/75A61K2039/505C07K2317/524C07K2317/53C07K2317/569
Inventor 格雷戈里·P·常安·F·张威廉·哈尼布拉德利·M·伦德比昂卡·普林茨
Owner DRAGONFLY THERAPEUTICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com